- Home
- KURA vs LQDA Comparison
KURA vs LQDA Comparison
Compare KURA & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- LQDA
- Stock Information
- Founded
- KURA 2014
- LQDA 2004
- Country
- KURA United States
- LQDA United States
- Employees
- KURA N/A
- LQDA N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- LQDA Health Care
- Exchange
- KURA Nasdaq
- LQDA Nasdaq
- Market Cap
- KURA 561.9M
- LQDA 1.2B
- IPO Year
- KURA N/A
- LQDA 2018
- Fundamental
- Price
- KURA $6.44
- LQDA $14.09
- Analyst Decision
- KURA Strong Buy
- LQDA Strong Buy
- Analyst Count
- KURA 12
- LQDA 9
- Target Price
- KURA $24.50
- LQDA $27.67
- AVG Volume (30 Days)
- KURA 1.4M
- LQDA 2.1M
- Earning Date
- KURA 08-07-2025
- LQDA 08-06-2025
- Dividend Yield
- KURA N/A
- LQDA N/A
- EPS Growth
- KURA N/A
- LQDA N/A
- EPS
- KURA N/A
- LQDA N/A
- Revenue
- KURA $67,991,000.00
- LQDA $14,144,000.00
- Revenue This Year
- KURA $125.04
- LQDA $189.27
- Revenue Next Year
- KURA $83.75
- LQDA $402.79
- P/E Ratio
- KURA N/A
- LQDA N/A
- Revenue Growth
- KURA N/A
- LQDA N/A
- 52 Week Low
- KURA $5.41
- LQDA $8.26
- 52 Week High
- KURA $23.48
- LQDA $19.41
- Technical
- Relative Strength Index (RSI)
- KURA 59.02
- LQDA 52.19
- Support Level
- KURA $5.65
- LQDA $11.86
- Resistance Level
- KURA $6.46
- LQDA $14.16
- Average True Range (ATR)
- KURA 0.26
- LQDA 0.71
- MACD
- KURA 0.07
- LQDA 0.21
- Stochastic Oscillator
- KURA 97.73
- LQDA 96.97
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.